全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Successful Outcome of Chronic Intrahepatic Cholestasis in an Adult Patient with Sickle Cell/β+ Thalassemia

DOI: 10.1155/2014/213631

Full-Text   Cite this paper   Add to My Lib

Abstract:

Sickle cell/ thalassemia (Hb S/ thal) is considered as a variant form of sickle cell disease. Acute episodes of vasoocclusive pain crisis are characteristic for sickle cell disorders and may be complicated by an acute or chronic life-threatening organ dysfunction. Chronic intrahepatic cholestasis is a rare and severe complication in sickle cell disease, characterized by marked hyperbilirubinemia and acute hepatic failure with an often fatal course. Despite the fact that patients with Hb S/ thal usually have a mild type of disease, herein we describe an interesting case of chronic intrahepatic cholestasis with successful outcome in an adult patient with Hb S/ thal. 1. Introduction Sickle cell/β+ thalassemia (Hb S/β+thal) is considered as a variant form of sickle cell disease (SCD). This condition is an inherited hemolytic anemia, associated with multiple acute and chronic complications such as painful vasoocclusive events, cerebral vasculopathy, priapism, liver, spleen, and renal and or lung disease. Chronic intrahepatic cholestasis is a rare and severe complication in sickle cell disease, characterized by marked hyperbilirubinemia and acute hepatic failure with an often fatal course. Despite the fact that patients with Hb S/β+thal usually have a mild type of disease, the low values of Hb A and Hb F might be associated sickle cell disease crises [1, 2]. We report an interesting case of chronic intrahepatic cholestasis with successful outcome in an adult patient with Hb S/β+thal. The patient gave consent to the publication of this report. 2. Case Report A 37 year Caucasian old male patient with known history of sickle cell disease and beta thalassemia (Hb S/β+thal) was attended to our outpatient clinic with a presenting symptom of worsening jaundice. Patient mentioned that he has stopped his regular schedule of exchange transfusions, which for the time being was inevitably his treatment regimen due to his refusal to continue hydroxycarbamide in order to procreate. The general condition of the patient was good. Physical examination was normal except the above-mentioned skin scleral jaundice and a palpable liver (4?cm below the costal margin) with no sign of pain. According to his past medical history, he had splenectomy at the age of 13 due to entrapment, cholecystectomy, right shin metaphysis osteomyelitis, and bilateral aseptic (avascular) hip necrosis. Interestingly, in the last two years the patient also suffered two recurrent episodes of painless cholestasis which resolved with exchange transfusions and hydroxycarbamide at 20?mg/kg per day (maximum

References

[1]  E. Vlachaki, M. Mainou, E. Bekiari, E. Vetsiou, and A. Tsapas, “Safety and efficacy of 4 years of deferasirox treatment for sickle cell disease patients,” Hemoglobin, vol. 37, no. 1, pp. 94–100, 2013.
[2]  D. B. Costa, R. A. Miksad, M. S. Buff, Y. Wang, and B. J. Dezube, “Case of fatal sickle cell intrahepatic cholestasis despite use of exchange transfusion in an African-American patient,” Journal of the National Medical Association, vol. 98, no. 7, pp. 1183–1187, 2006.
[3]  W. E. Norris, “Acute hepatic sequestration in sickle cell disease,” Journal of the National Medical Association, vol. 96, no. 9, pp. 1235–1239, 2004.
[4]  N. Zakaria, A. Knisely, B. Portmann et al., “Acute sickle cell hepatopathy represents a potential contraindication for percutaneous liver biopsy,” Blood, vol. 101, no. 1, pp. 101–103, 2003.
[5]  A. Chehal, A. Taher, and A. Shamseddine, “Sicklemia with multi-organ failure syndrome and thrombotic thrombocytopenic purpura,” Hemoglobin, vol. 26, no. 4, pp. 345–351, 2002.
[6]  A. O'Callaghan, S. G. O'Brien, M. Ninkovic et al., “Chronic intrahepatic cholestasis in sickle cell disease requiring exchange transfusion,” Gut, vol. 37, no. 1, pp. 144–147, 1995.
[7]  P. A. Berry, T. J. S. Cross, S. L. Thein et al., “Hepatic dysfunction in sickle cell disease: a new system of classification based on global assessment,” Clinical Gastroenterology and Hepatology, vol. 5, no. 12, pp. 1469–1476, 2007.
[8]  M. R. Jeng, M. D. Rieman, P. E. Naidu et al., “Resolution of chronic hepatic sequestration in a patient with homozygous sickle cell disease receiving hydroxyurea,” Journal of Pediatric Hematology/Oncology, vol. 25, no. 3, pp. 257–260, 2003.
[9]  C. S. R. Hatton, C. Bunch, and D. J. Weatherall, “Hepatic sequestration in sickle cell anaemia,” British Medical Journal, vol. 290, no. 6470, pp. 744–745, 1985.
[10]  C. Tafrali, A. Paizi, J. Borg, et al., “Genomic variation in the MAP3K5 gene is associated with β-thalassemia disease severity and hydroxyurea treatment efficacy,” Pharmacogenomics, vol. 14, no. 5, pp. 469–483, 2013.
[11]  R. E. Ware, “How I use hydroxyurea to treat young patients with sickle cell anemia,” Blood, vol. 115, no. 26, pp. 5300–5311, 2010.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413